Ascentage Pharma Group International (AAPG) Total Non-Current Liabilities (2023 - 2025)
Ascentage Pharma Group International (AAPG) posted quarterly Total Non-Current Liabilities of $139.0 million for Q4 2025, down 15.16% year-over-year from $163.9 million in Q4 2024, and down 15.16% quarter-over-quarter from $163.9 million in Q4 2024.
Powered by 
Analysis
Ascentage Pharma Group International (AAPG) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Ascentage Pharma Group International's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $139.0 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 15.16% year-over-year to $139.0 million; the TTM figure through Dec 2025 stood at $139.0 million (down 15.16% YoY), while the FY2025 annual figure was $141.0 million, down 12.56% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $139.0 million, down from $163.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $207.7 million in Q4 2023, with the low at $139.0 million in Q4 2025.
- The 3-year median for Total Non-Current Liabilities is $163.9 million (2024), against an average of $170.2 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities declined 21.11% in 2024, then retreated 15.16% in 2025.
- Ascentage Pharma Group International's Total Non-Current Liabilities stood at $207.7 million in 2023, then fell by 21.11% to $163.9 million in 2024, then declined by 15.16% to $139.0 million in 2025.
- Business Quant data shows AAPG's Total Non-Current Liabilities at $139.0 million in Q4 2025, $163.9 million in Q4 2024, and $207.7 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Ascentage Pharma Group International | 1.57 Bn | 1.29 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 139.02 Mn |
| Dec 31, 2024 | 163.86 Mn |
| Dec 31, 2023 | 207.72 Mn |